Episode Details

The rare disease space is often overlooked, but it may be the most important laboratory we have for the future of medicine. Jimmy sits down with Rob Freishtat, board member of the Foundation for mRNA Medicines, to talk about what is actually driving collaboration between academic institutions and industry, what a changing regulatory landscape means for sites, and why financial viability and patient access are not as opposed as people think. Tune in now.